US2010135969A1PendingUtilityA1

Method of treating cancer using platelet releasate

Assignee: MISHRA ALLANPriority: Dec 29, 2003Filed: Feb 4, 2010Published: Jun 3, 2010
Est. expiryDec 29, 2023(expired)· nominal 20-yr term from priority
Inventors:Allan Mishra
A61P 35/00A61K 41/13C12N 5/0018C12N 2501/305A61K 35/16C12N 2502/11C12N 2500/60C12N 2500/00C12N 2500/84A61K 35/19A61K 35/28C12N 5/0644A61K 35/15
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer.

Claims

exact text as granted — not AI-modified
1 . A formulation for treating cancer, comprising:
 a component of blood obtained from a patient to be treated; and   a pharmaceutically acceptable carrier.   
   
   
       2 . The formulation of  claim 1 , wherein the component of blood is platelet-rich-plasma (PRP). 
   
   
       3 . The formulation of  claim 2 , wherein the PRP is subjected to energy waves to form a platelet releasate. 
   
   
       4 . The formulation of  claim 3 , wherein a protein component of the platelet releasate is removed. 
   
   
       5 . The formulation of  claim 3 , wherein a plurality of components of the platelet releasate are removed. 
   
   
       6 . The formulation of  claim 3 , further comprising:
 a recombinantly produced human protein.   
   
   
       7 . The formulation of  claim 1 , wherein the carrier is an injectable carrier. 
   
   
       8 . The formulation of  claim 7 , wherein the injectable carrier comprises a pH buffering agent. 
   
   
       9 . The formulation of  claim 3 , wherein substantially all human growth hormone naturally present in the platelet releasate is removed. 
   
   
       10 . The formulation of  claim 3 , further comprising:
 biocarbonate buffer in a molarity sufficient to adjust formulation pH to within a range of about 7.2 to about 7.6.   
   
   
       11 . A method, comprising:
 extracting blood from a patient;   concentrating platelets from the blood;   processing the platelets in a manner which breaks open the platelets and obtaining a platelet releasate; and   administering the platelet releasate to the patient.   
   
   
       12 . The method of  claim 11 , wherein the processing comprises exposing the platelets to energy waves. 
   
   
       13 . The method of  claim 11 , wherein the administering comprises injecting the platelet releasate into a tumor of the patient. 
   
   
       14 . The method of  claim 1 , wherein the administering comprises injecting the platelet releasate into a cancerous tumor of the patient. 
   
   
       15 . The method of  claim 14 , further comprising:
 separating a substantially all growth factor protein from the platelet releasate prior to administering the platelet releasate to the patient.   
   
   
       16 . A method of treating cancer, comprising:
 extracting blood from a patient;   concentrating platelets from the blood;   processing the platelets in a manner which breaks open the platelets obtaining a platelet releasate;   formulating the platelet releasate into an injectable formulation buffered to a pH of 7.4±5%; and   administering a therapeutically effective amount of the formulation to a patient.   
   
   
       17 . The method of  claim 9  wherein the patient treated with the formulation is the same patient from which the blood is extracted from, and the formulation is buffered to pH 7.4±2%; and wherein the platelets are processed for a period of time and under conditions so as to break open 90% or more of the platelets; and further wherein the patient from which the blood is extracted is the same patient to which the formulation is administered. 
   
   
       18 . The method of  claim 17 , further comprising:
 repeatedly administering a therapeutically effective amount of the formulation to the patient over a period of time while monitoring the patient and adjusting dosing to effectively treat the cancer.   
   
   
       19 . A method of treatment, comprising:
 extracting blood from a patient;   concentrating platelets from the blood;   processing the platelets in a manner which breaks open the platelets obtaining a platelet releasate;   placing cells on a culture median comprising the platelet releasate;   allowing the cells to proliferate on the culture medium;   isolating the cultured cells;   formulating the isolated cells into an injectable formulations; and   administering the injectable formulation to a patient.   
   
   
       20 . The method of  claim 19 , wherein the cells placed on the culture medium are obtained from the same patient the blood is extracted and the cells are from the patient's bone marrow prior to subjecting the patient to radiation;
 wherein the ultrasound processing is carried out for a period of time and under conditions so as to break open 90% or more of the platelets; and   wherein the blood is extracted from the same patient as the cells and the cells comprise adult stem cells.   
   
   
       21 . A method of culturing cells, comprising:
 isolating cells from a patient;   placing the cells on a medium comprising platelet-rich plasma; and   allowing the cells to proliferate.   
   
   
       22 . The method of  claim 21 , wherein the isolated cells are extracted from the patient's bone marrow which cells are isolated from the same patient as the platelets of the platelet-rich plasma are obtained. 
   
   
       23 . A method of treating cancer, comprising:
 extracting blood from a patient;   concentrating platelets from the blood;   processing the platelets in a manner which breaks open the platelets obtaining a platelet releasate;   formulating the platelet releasate into an injectable formulation buffered to a pH of 7.4±5%;   surgically removing a cancerous tumor from a patient; and   administering a therapeutically effective amount of the formulation to an area where the tumor was removed.   
   
   
       24 . The method of  claim 23  wherein the patient treated with the formulation is the same patient from which the blood is extracted from, and the formulation is buffered to pH 7.4±2%; and
 wherein the platelets are processed for a period of time and under conditions so as to break open 95% or more of the platelets; and   wherein the patient from which the blood is extracted is the same patient from which tumor is removed and the formulation is administered.   
   
   
       25 . The method of  claim 24 , further comprising:
 repeatedly administering a therapeutically effective amount of the formulation to the area where the tumor was removed over a period of time while monitoring the patient and adjusting dosing.   
   
   
       26 . A method of treating cancer, comprising the steps of:
 isolating white blood cells from a patient;   subjecting the white blood cells to a treatment whereby cell membranes are opened and a white blood cell releasate obtained;   formulating the white blood cell releasate to create an injectable formulation; and   injecting the formulation into a patient.   
   
   
       27 . The method of  claim 26 , further comprising:
 sorting the white blood cells prior to treatment and isolating a desired type of white blood cell for treatment and the formulation is injected into a cancerous tumor of the patient.   
   
   
       28 . The method of  claim 27 , wherein the patient from which the white blood cells are isolated is the same patient to which the formulation is injected.

Join the waitlist — get patent alerts

Track US2010135969A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.